Incannex Healthcare (IXHL) Total Non-Current Liabilities (2020 - 2026)
Incannex Healthcare (IXHL) posted Total Non-Current Liabilities of $2.0 million for Q1 2026, down 73.65% sequentially from $7.5 million in Q1 2025, and down 73.65% YoY from $7.5 million in Q1 2025.
Incannex Healthcare (IXHL) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Incannex Healthcare has reported Total Non-Current Liabilities for 6 years, with the latest figure at $2.0 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 73.65% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 73.65% YoY) and the FY2023 annual result came in at $616087.0, changed N/A from the prior year.
- Total Non-Current Liabilities eased to $2.0 million in Q1 2026 per IXHL's latest filing, from $7.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $8.9 million in Q4 2024 and troughed at $181519.0 in Q4 2022.
- A 5-year average of $3.8 million and a median of $2.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities soared 1821.01% in 2023, then plunged 73.65% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $181519.0 in 2022, then jumped by 1821.01% to $3.5 million in 2023, then soared by 153.94% to $8.9 million in 2024, then dropped by 15.62% to $7.5 million in 2025, then slumped by 73.65% to $2.0 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $2.0 million, $7.5 million, and $8.9 million for Q1 2026, Q1 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Incannex Healthcare | 43.22 Mn | 43.22 Mn | - | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.97 Mn |
| Mar 31, 2025 | 7.47 Mn |
| Dec 31, 2024 | 8.86 Mn |
| Dec 31, 2023 | 3.49 Mn |
| Jun 30, 2023 | 616,087.00 |
| Dec 31, 2022 | 181,519.00 |
| Jun 30, 2020 | 955,006.00 |